Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Experts’ conclave to pave holistic approach to cancer management
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Subscribe To Our Newsletter & Stay Updated
